{"id":127955,"date":"2026-09-09T01:40:48","date_gmt":"2026-09-09T01:40:48","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/127955\/"},"modified":"2026-09-09T01:40:48","modified_gmt":"2026-09-09T01:40:48","slug":"shinhan-securities-cuts-alteogen-target-to-%e2%82%a9520000-after-novartis-aoc-phase-3-failure-biggo-finance","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/127955\/","title":{"rendered":"Shinhan Securities Cuts Alteogen Target to \u20a9520,000 After Novartis AOC Phase 3 Failure \u2014 BigGo Finance"},"content":{"rendered":"<p>Shinhan Securities has lowered its target price for Alteogen from \u20a9540,000 (approximately $400) to \u20a9520,000 (approximately $390), following the failure of one of Novartis&#8217;s antibody-oligonucleotide conjugate (AOC) drug candidates to meet its primary endpoint in a Phase 3 clinical trial.<\/p>\n<p>In a report released on the 9th, Shinhan Securities stated, &#8220;Following the Phase 3 failure of Del-desiran, the number of confirmed subcutaneous (SC) conversion products has been revised from three to two.&#8221; The downgrade comes just six days after the brokerage raised its target price from \u20a9480,000 (approximately $360) to \u20a9540,000 on the 3rd.<\/p>\n<p>At that time, Shinhan Securities had significantly raised its target price to reflect the SC conversion value of three AOC products, immediately following the signing of a \u20a94.416 trillion (approximately $3.3 billion) technology transfer agreement between Alteogen and Novartis. However, with Del-desiran\u2014which was being developed as a treatment for myotonic dystrophy type 1\u2014failing to demonstrate efficacy in Phase 3, part of that valuation has been rolled back.<\/p>\n<p>Eom Min-yong, an analyst at Shinhan Securities, explained, &#8220;We had estimated Del-desiran as an SC development candidate based on its intravenous (IV) administration schedule of once every eight weeks over 54 weeks, but the future development strategy has now become uncertain.&#8221; He added, &#8220;We are removing Del-desiran from the expected AOC SC conversion list, reducing the count from three to two.&#8221;<\/p>\n<p>Novartis shares closed down 9.9% at \u20a9277,000 (approximately $210) the previous day and continued to show weakness in morning trading.<\/p>\n<p>However, the brokerage maintained its Buy rating and top-pick status within the sector, citing the smooth progress of the remaining two AOC pipeline candidates. Eom noted, &#8220;Del-zota has completed its U.S. Food and Drug Administration (FDA) approval application and is on track for approval in the first half of 2027, with no changes to its SC development plans.&#8221; He added that Del-Brax is also being developed with a peak sales target of up to $4 billion, meaning the SC development value of both candidates continues to be reflected in the valuation.<\/p>\n<p>The impact on the contract itself is expected to be limited. Eom stated, &#8220;There will be no return of upfront payments, nor any reduction or modification of the existing contract due to the Del-desiran failure.&#8221; He projected that &#8220;SC development for a total of 10 products, including antibody-drug conjugates (ADCs) and bispecific antibodies, is anticipated going forward.&#8221;<\/p>\n<p>Alteogen signed a technology transfer agreement with Novartis on the 2nd of this month, worth up to \u20a94.416 trillion, covering SC formulation conversion using its human hyaluronidase technology &#8216;ALT-B4.&#8217; The market had expected this deal to expand ALT-B4&#8217;s application scope into RNA-based therapies, including AOCs.<\/p>\n<p>The consensus view across the securities industry is that this clinical failure does not undermine the overall contract. Since Del-desiran was initially classified as an SC conversion candidate but its development strategy has now become uncertain, the actual impact on Alteogen&#8217;s technology transfer value is considered minimal.<\/p>\n<p>In fact, the potential for future pipeline expansion remains intact. The SC development options for Novartis&#8217;s 10 products, including ADCs and bispecific antibodies, remain unchanged, and there is also the possibility that other AOC candidates could be newly added to replace Del-desiran.<\/p>\n","protected":false},"excerpt":{"rendered":"Shinhan Securities has lowered its target price for Alteogen from \u20a9540,000 (approximately $400) to \u20a9520,000 (approximately $390), following&hellip;\n","protected":false},"author":2,"featured_media":127956,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[42023,60732,60731,42219,62199,62270,62406,206,62405],"class_list":["post-127955","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-del-brax","tag-alt-b4","tag-alteogen","tag-aoc","tag-del-desiran","tag-del-zota","tag-eom-min-yong","tag-novartis","tag-shinhan-securities"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117238542227331484","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/127955","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=127955"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/127955\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/127956"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=127955"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=127955"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=127955"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}